Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

  • Biosimilar Hyrimoz™ (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity †
  • Biosimilars are critical to sustaining US healthcare system, providing broader access to vital treatments for prevalent chronic conditions such as psoriasis and rheumatoid arthritis, which affect over eight million Americans combined
  • Hyrimozis third FDA-approved Sandoz biosimilar in US

 

Holzkirchen, Germany, October 31, 2018 — Sandoz, a Novartis division and the pioneer …

/by

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

  • Net sales grew 6% (cc[1], +3% USD) mainly driven by:
    • Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications
    • Entresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide
    • Promacta/Revolade USD 295 million (+32% cc), Tafinlar + Mekinist USD 291 million (+33% cc) and Jakavi USD 248 million (+27% cc) continued strong double-digit growth
    • AAA sales of USD 105 million, driven by the strong launch of …
/by

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

  • Net sales grew 6% (cc[1], +3% USD) mainly driven by:
    • Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications
    • Entresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide
    • Promacta/Revolade USD 295 million (+32% cc), Tafinlar + Mekinist USD 291 million (+33% cc) and Jakavi USD 248 million (+27% cc) continued strong double-digit growth
    • AAA sales of USD 105 million, driven by the strong launch of …
/by

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

  • Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®**
  • Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023

Holzkirchen, October 11, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for …

/by

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

  • Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®**
  • Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023

Holzkirchen, October 11, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for …

/by

Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

  • Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need
  • Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenges
  • Three shortlisted entrants will attend South by Southwest (SXSW), where Sandoz will work with them to create scalable solutions that could improve people’s lives

Holzkirchen, October 4, 2018 – Sandoz, the Novartis generics and biosimilars division, today …

/by

Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

  • Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need
  • Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenges
  • Three shortlisted entrants will attend South by Southwest (SXSW), where Sandoz will work with them to create scalable solutions that could improve people’s lives

Holzkirchen, October 4, 2018 – Sandoz, the Novartis generics and biosimilars division, today …

/by

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

  • Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
  • Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
  • Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …
/by

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

  • Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
  • Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
  • Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …
/by

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

  • Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.
     
  • Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion
     
  • Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US

Basel, September 6, 2018 – Novartis …

/by